Ethanol effects on drug release from Verapamil Meltrex®, an innovative melt extruded formulation

International Journal of Pharmaceutics

Volumn 368, Issue 1-2, 2009, Pages 72-75

  Roth, W ^a   Setnik, B ^b   Zietsch, M ^a   Burst, A ^a   Breitenbach, J ^a   Sellers, E ^b   Brennan, D ^c  

^a ABBOTT GMBH AND CO KG   (Germany)

^b DecisionLine Clinical Research Corporation   (Canada)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Controlled release formulation; Dissolution; Ethanol; In vitro; Melt extrusion

Indexed keywords

ALCOHOL; ANTIANGINA PECTORIS AGENT; UNCLASSIFIED DRUG; VERAHEXAL; VERAPAMIL; VERAPAMIL MELTREX; VERAPAMIL RETARD RATIOPHARM;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; MELT EXTRUDED FORMULATION; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ETHANOL; SOLUBILITY; TABLETS; TIME FACTORS; VERAPAMIL;

EID: 58949096652     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.09.052     Document Type: Article

References (12)

1. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54 (2002) 107-117
2. Breitenbach J., and Lewis J. Two concepts, one technology: controlled-release and solid dispersions with Meltrex. Modified-Release Drug Delivery Technology (2003), Marcel Dekker Inc. pp. 125-134
3. Cassilly D., Kantor S., Knight L.C., Maurer A.H., Fisher R.S., Semler J., and Parkman H.P. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol. Motil. 20 (2008) 311-319
4. Kelly K.A. Gastric emptying of liquids and solids: roles of proximal and distal stomach. Am. J. Physiol. 230 (1980) G71-G76
5. Lynch T., and Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76 (2007) 348-351
6. Masubichi Y., and Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol. 37 (2007) 389-412
7. McColl S., and Sellers E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol. Depend. 83 (2006) S52-S62
8. Product Monograph Covera-HS™ (verapamil hydrochloride) controlled-onset extended release tablets, 2006. Pfizer Canada Inc.
9. Schwartz R.H., Milteer R., and LeBeau M.A. Drug-facilitated sexual assault ('date rape'). South Med. J. 93 (2001) 655-656
10. U.S. Food and Drug Administration alert for healthcare professionals, 2005. Alcohol-Palladone™ interaction.
11. Vourvahis M., and Kashuba A.D. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated it ritonavir-enhanced tipranavir. Pharmacotherapy 27 (2007) 888-909
12. World Health Organization Global Status Report on Alcohol, 2004.